Temozolomide in malignant gliomas: Current use and future targets

J. Lee Villano, Tara E. Seery, Linda R. Bressler

Research output: Contribution to journalShort surveypeer-review

157 Scopus citations


Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

Original languageEnglish
Pages (from-to)647-655
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Issue number4
StatePublished - Sep 2009


  • Alkylating chemotherapy
  • Brain tumor
  • Glioblastoma
  • Malignant glioma
  • Temozolomide
  • Tumor resistance

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Temozolomide in malignant gliomas: Current use and future targets'. Together they form a unique fingerprint.

Cite this